McKesson Corp. (MCK)
775.32
+14.75
(+1.94%)
USD |
NYSE |
May 18, 12:31
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 93.20B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 8.04% |
| Valuation | |
| PE Ratio | 20.16 |
| PE Ratio (Forward) | |
| PS Ratio | 0.2384 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | 0.82 |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -3.966 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 23.91% |
Profile
| McKesson Corp. engages in providing healthcare services. It operates through the following segments: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions (RxTS), and Medical-Surgical Solutions. The North American Pharmaceutical segment focuses on distribution of branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs to customers in U.S. and Canada. The Oncology and Multispecialty segment includes provision of solutions that includes specialty drug distribution, group purchasing organizations, infusion services, direct to patient pharmacy capabilities, InspiroGene cell and gene therapy services, technology solutions, practice consulting services, and vaccine distribution. The RxTS segment focuses on solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX. |
| URL | http://www.mckesson.com |
| Investor Relations URL | https://investor.mckesson.com |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | Aug. 05, 2026 (est.) |
| Last Earnings Release | May. 07, 2026 |
| Next Ex-Dividend Date | Jun. 01, 2026 |
| Last Ex-Dividend Date | Mar. 02, 2026 |
Profile
| McKesson Corp. engages in providing healthcare services. It operates through the following segments: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions (RxTS), and Medical-Surgical Solutions. The North American Pharmaceutical segment focuses on distribution of branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs to customers in U.S. and Canada. The Oncology and Multispecialty segment includes provision of solutions that includes specialty drug distribution, group purchasing organizations, infusion services, direct to patient pharmacy capabilities, InspiroGene cell and gene therapy services, technology solutions, practice consulting services, and vaccine distribution. The RxTS segment focuses on solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX. |
| URL | http://www.mckesson.com |
| Investor Relations URL | https://investor.mckesson.com |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | Aug. 05, 2026 (est.) |
| Last Earnings Release | May. 07, 2026 |
| Next Ex-Dividend Date | Jun. 01, 2026 |
| Last Ex-Dividend Date | Mar. 02, 2026 |